{"id":124,"date":"2026-07-26T20:28:39","date_gmt":"2026-07-26T20:28:39","guid":{"rendered":"https:\/\/findpeptideclinics.com\/blog\/?p=124"},"modified":"2026-08-16T22:27:46","modified_gmt":"2026-08-16T22:27:46","slug":"fda-peptide-vote-bpc-157-tb-500-compounding","status":"publish","type":"post","link":"https:\/\/findpeptideclinics.com\/blog\/fda-peptide-vote-bpc-157-tb-500-compounding\/","title":{"rendered":"FDA Advisory Panel Peptide Vote (July 2026): Evidence Cards for BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and Emideltide"},"content":{"rendered":"

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) met July 23\u201324, 2026<\/strong> to discuss seven peptide-related bulk drug substances being considered for the 503A Bulks List. That list is one of three bulk-substance pathways described in section 503A; appearing on it is not the only condition a compounder must satisfy. After the meeting, contemporaneous news reports said the committee recommended six of the seven<\/strong>.<\/p>\n

A committee recommendation is not<\/strong> FDA approval, a final rule, a prescription, a safety finding, or proof that a clinic can offer a peptide today. This page gives one dated evidence card per compound, separates what FDA staff reviewed from what the committee recommended from what the law actually is, and lists what the vote did not<\/em> do.<\/p>\n

Read this first:<\/strong> as of 2026-08-16<\/strong>, the current text of 21 CFR 216.23<\/a> lists six other substances and none of the seven discussed at this meeting. An advisory vote does not amend that regulation. See the peptide tracker<\/a> for the live status of every compound covered here.<\/p>\n

The three steps patients mix up<\/h2>\n

Every claim about this vote should be tested against three separate things:<\/p>\n

    \n
  1. FDA written review.<\/strong> FDA published a briefing that proposed not adding either form of all seven substances<\/strong> after reviewing characterization, historical use, effectiveness, and safety. That was the agency’s written proposal, not a staff roll-call vote.<\/li>\n
  2. Advisory-committee recommendation.<\/strong> The PCAC \u2014 independent outside experts \u2014 voted. Its advice is non-binding<\/strong>; FDA “generally follows the recommendations but is not legally bound to do so.”<\/li>\n
  3. Current regulation.<\/strong> FDA addresses additions to the 503A list through notice-and-comment rulemaking. The committee vote itself did not change the current list in 21 CFR 216.23<\/a>.<\/li>\n<\/ol>\n

    Seven evidence cards (current as of 2026-08-16)<\/h2>\n

    1. BPC-157<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nUlcerative colitis<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> found insufficient evidence to conclude that BPC-157 is effective for ulcerative colitis and identified characterization, safety, and immunogenicity concerns.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nRecommended (reported 8\u20136 with one abstention).<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\nDid not approve BPC-157, prove it works for ulcerative colitis, or validate recovery, injury, or anti-aging marketing.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    2. KPV<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nWound healing and inflammatory conditions<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> said neither the nomination nor FDA’s search identified clinical studies of KPV administered in humans for the evaluated uses.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nRecommended.<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\nDid not turn a broad “anti-inflammatory” claim into an FDA-reviewed indication.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    3. TB-500<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nWound healing<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> found no clinical evidence for wound healing and no human-use information sufficient to assess safety or effectiveness.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nRecommended.<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\nDid not convert athletic-recovery language into human-outcome proof.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    4. MOTS-c<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nObesity and osteoporosis (FDA lists the spelling “MOTs-C”)<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> found no clinical studies administering MOTS-c-related substances to humans for the evaluated uses.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nRecommended.<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\nDid not create a longevity, metabolism, or energy promise.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    5. Semax<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nCerebral ischemia, migraine, and trigeminal neuralgia<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> found insufficient evidence for cerebral ischemia, migraine, or trigeminal neuralgia; the limited studies had major design and reporting problems.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nRecommended.<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\nDid not give FDA-reviewed support to focus, mood, or productivity claims.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    6. Epitalon<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nInsomnia<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> found no clinical safety data for human use and insufficient evidence of effectiveness for insomnia.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nRecommended.<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\nDid not endorse anti-aging or longevity language as the reviewed use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    7. Emideltide (DSIP)<\/h3>\n\n\n\n\n\n\n\n\n\n
    Field<\/th>\nFinding<\/th>\n<\/tr>\n<\/thead>\n
    Use FDA evaluated<\/td>\nOpioid withdrawal, chronic insomnia, and narcolepsy<\/td>\n<\/tr>\n
    FDA’s evidence conclusion<\/td>\nThe official briefing<\/a> found limited, poorly controlled evidence and insufficient safety and effectiveness information for chronic insomnia, narcolepsy, and opioid withdrawal.<\/td>\n<\/tr>\n
    Committee recommendation<\/td>\nNot recommended<\/strong> (rejected).<\/td>\n<\/tr>\n
    Current regulatory status<\/td>\nNot listed in the current text of 21 CFR 216.23; the unfavorable advisory recommendation did not amend the list.<\/td>\n<\/tr>\n
    What the vote did not<\/strong> do<\/td>\n“Sleep peptide” marketing is not committee support; the committee declined to recommend access.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Comparison table<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
    Peptide<\/th>\nUse FDA evaluated<\/th>\nCommittee recommendation<\/th>\nLegal\/rulemaking status (2026-08-16)<\/th>\n<\/tr>\n<\/thead>\n
    BPC-157<\/td>\nUlcerative colitis<\/td>\nRecommended (reported 8\u20136, one abstention)<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n
    KPV<\/td>\nWound healing \/ inflammatory conditions<\/td>\nRecommended<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n
    TB-500<\/td>\nWound healing<\/td>\nRecommended<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n
    MOTS-c<\/td>\nObesity \/ osteoporosis<\/td>\nRecommended<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n
    Semax<\/td>\nCerebral ischemia \/ migraine \/ trigeminal neuralgia<\/td>\nRecommended<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n
    Epitalon<\/td>\nInsomnia<\/td>\nRecommended<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n
    Emideltide (DSIP)<\/td>\nOpioid withdrawal \/ chronic insomnia \/ narcolepsy<\/td>\nNot recommended<\/td>\nNot in current 21 CFR 216.23<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    What the vote did not do<\/h2>\n